# Fate Therapeutics Inc: filings

FATE · Nasdaq · CIK 1434316 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fate.md) · [Financials](/companies/fate/financials.md) · [Filings](/companies/fate/filings.md) · [Insiders](/companies/fate/insiders.md)

## Reports and events: 223 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 357, 8-K 132, 10-Q 39, 3 37, SC 13G/A 36, 144 31, S-8 17, SC 13G 15, 10-K 13, 424B5 13, CORRESP 13, DEF 14A 13, DEFA14A 12, SC 13D/A 11, D 9, UPLOAD 9, CT ORDER 8, EFFECT 8, 4/A 7, S-3 7, ARS 5, PRE 14A 4, S-1/A 4, 424B3 3, SC 13D 3, SCHEDULE 13D/A 3, SCHEDULE 13G/A 3, 10-Q/A 2, 8-K/A 2, D/A 2, DRSLTR 2, FWP 2, S-3ASR 2, 3/A 1, 424B4 1, 8-A12B 1, CERTNAS 1, DRS 1, DRS/A 1, S-1 1, SCHEDULE 13G 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-28 | 08:10 ET | [8-K](/filings/0001193125-26-403429.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-403429 |
| 2026-08-13 | 08:34 ET | [10-Q](/filings/0001193125-26-347988.md) | Quarterly report, period 2026-06-30 | 0001193125-26-347988 |
| 2026-08-13 | 08:31 ET | [8-K](/filings/0001193125-26-347984.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-347984 |
| 2026-06-15 | 16:02 ET | [8-K](/filings/0001193125-26-271055.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-271055 |
| 2026-06-04 | 16:37 ET | [8-K](/filings/0001193125-26-257558.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-257558 |
| 2026-05-13 | 08:34 ET | [10-Q](/filings/0001193125-26-220696.md) | Quarterly report, period 2026-03-31 | 0001193125-26-220696 |
| 2026-05-13 | 08:32 ET | [8-K](/filings/0001193125-26-220691.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-220691 |
| 2026-04-24 | 16:03 ET | [DEF 14A](/filings/0001193125-26-177094.md) | Proxy statement, period 2026-06-12 | 0001193125-26-177094 |
| 2026-04-22 | 21:47 ET | [SCHEDULE 13D/A](/filings/0001104659-26-047066.md) | Ownership report, active investor, amended | 0001104659-26-047066 |
| 2026-02-26 | 09:07 ET | [10-K](/filings/0001193125-26-073699.md) | Annual report, period 2025-12-31 | 0001193125-26-073699 |
| 2026-02-26 | 09:04 ET | [8-K](/filings/0001193125-26-073689.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-073689 |
| 2025-11-13 | 08:35 ET | [10-Q](/filings/0001193125-25-279096.md) | Quarterly report, period 2025-09-30 | 0001193125-25-279096 |
| 2025-11-13 | 08:32 ET | [8-K](/filings/0001193125-25-279091.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-279091 |
| 2025-10-27 | 07:00 ET | [8-K](/filings/0001193125-25-250674.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-250674 |
| 2025-10-14 | 16:02 ET | [8-K](/filings/0001193125-25-238989.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-238989 |
| 2025-08-12 | 16:09 ET | [10-Q](/filings/0000950170-25-107309.md) | Quarterly report, period 2025-06-30 | 0000950170-25-107309 |
| 2025-08-12 | 16:07 ET | [8-K](/filings/0001193125-25-178947.md) | 2.02 Results of operations; 2.05 Exit or disposal costs; 9.01 Financial statements and exhibits | 0001193125-25-178947 |
| 2025-07-03 | 16:01 ET | [SCHEDULE 13D/A](/filings/0001104659-25-065772.md) | Ownership report, active investor, amended | 0001104659-25-065772 |
| 2025-06-17 | 16:01 ET | [8-K/A](/filings/0001193125-25-142037.md) | 5.07 Shareholder vote results | 0001193125-25-142037 |
| 2025-05-30 | 17:15 ET | [8-K](/filings/0001193125-25-132301.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-132301 |
| 2025-05-13 | 16:03 ET | [10-Q](/filings/0000950170-25-070285.md) | Quarterly report, period 2025-03-31 | 0000950170-25-070285 |
| 2025-05-13 | 16:02 ET | [8-K](/filings/0000950170-25-070280.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-070280 |
| 2025-04-17 | 16:05 ET | [DEF 14A](/filings/0001193125-25-084310.md) | Proxy statement, period 2025-05-29 | 0001193125-25-084310 |
| 2025-03-05 | 16:03 ET | [10-K](/filings/0000950170-25-033510.md) | Annual report, period 2024-12-31 | 0000950170-25-033510 |
| 2025-03-05 | 16:02 ET | [8-K](/filings/0000950170-25-033507.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-033507 |
| 2025-01-06 | 16:01 ET | [8-K](/filings/0001193125-25-002153.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-25-002153 |
| 2024-12-26 | 21:00 ET | [SCHEDULE 13D/A](/filings/0001104659-24-131793.md) | Ownership report, active investor, amended | 0001104659-24-131793 |
| 2024-11-29 | 14:33 ET | [8-K](/filings/0001193125-24-268003.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-268003 |
| 2024-11-12 | 16:03 ET | [10-Q](/filings/0000950170-24-125317.md) | Quarterly report, period 2024-09-30 | 0000950170-24-125317 |
| 2024-11-12 | 16:01 ET | [8-K](/filings/0000950170-24-125307.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125307 |
| 2024-08-30 | 16:21 ET | [8-K](/filings/0001193125-24-211130.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-211130 |
| 2024-08-13 | 16:08 ET | [10-Q](/filings/0000950170-24-096187.md) | Quarterly report, period 2024-06-30 | 0000950170-24-096187 |
| 2024-08-13 | 16:06 ET | [8-K](/filings/0000950170-24-096177.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-096177 |
| 2024-07-31 | 16:03 ET | [8-K](/filings/0001193125-24-189911.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-189911 |
| 2024-06-10 | 16:31 ET | [8-K](/filings/0001193125-24-158374.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-24-158374 |
| 2024-06-07 | 17:26 ET | [8-K](/filings/0001193125-24-157554.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-24-157554 |
| 2024-05-31 | 17:24 ET | [8-K](/filings/0001193125-24-151963.md) | 5.02 Departure or appointment of officers or directors | 0001193125-24-151963 |
| 2024-05-09 | 16:05 ET | [10-Q](/filings/0000950170-24-056869.md) | Quarterly report, period 2024-03-31 | 0000950170-24-056869 |
| 2024-05-09 | 16:02 ET | [8-K](/filings/0000950170-24-056852.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-056852 |
| 2024-05-09 | 09:01 ET | [8-K](/filings/0001193125-24-134840.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-134840 |
| 2024-04-26 | 16:06 ET | [DEF 14A](/filings/0001193125-24-117981.md) | Proxy statement, period 2024-06-07 | 0001193125-24-117981 |
| 2024-03-25 | 17:15 ET | [SC 13D/A](/filings/0001104659-24-038492.md) | Ownership report, active investor, amended | 0001104659-24-038492 |
| 2024-03-21 | 17:32 ET | [8-K](/filings/0001193125-24-072871.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-072871 |
| 2024-02-26 | 16:10 ET | [10-K](/filings/0000950170-24-020158.md) | Annual report, period 2023-12-31 | 0000950170-24-020158 |
| 2024-02-26 | 16:03 ET | [8-K](/filings/0000950170-24-020123.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-020123 |
| 2023-12-28 | 16:53 ET | [SC 13D/A](/filings/0001104659-23-130098.md) | Ownership report, active investor, amended | 0001104659-23-130098 |
| 2023-11-08 | 17:10 ET | [8-K](/filings/0001193125-23-273633.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001193125-23-273633 |
| 2023-11-08 | 16:05 ET | [10-Q](/filings/0000950170-23-061080.md) | Quarterly report, period 2023-09-30 | 0000950170-23-061080 |
| 2023-11-08 | 16:03 ET | [8-K](/filings/0000950170-23-061077.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-061077 |
| 2023-09-01 | 17:29 ET | [8-K](/filings/0001193125-23-227749.md) | 8.01 Other events | 0001193125-23-227749 |

Page 1 of 5. [Older](/companies/fate/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:08 ET. No prices; not investment advice.